Список проголосовавших за комментарий " Gapping up/down: MU +13% after earnings, UAA +4% and PVH +1% after upgrades; FINL -15%, GME -11% and OXM -9% after earnings, M -1% after dg<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>HTGM</strong> +70.7%, (also announces that its HTG EdgeSeq technology has been successfully adapted for use with the QIAGEN GeneReader NGS System based on the results of initial technical feasibility tests)</li><li><strong>ZAIS</strong> +39.4%, <strong>EBIO</strong> +21.1%, <strong>NVCN</strong> +14.9%, <strong>MU</strong> +13.2%, <strong>LTBR</strong> +12.2%, <strong>VSTM</strong> +6%, <strong>JAG</strong> +5.4%, <strong>SPP</strong> +3.9%, <strong>CYTX</strong> +1.2%, <strong>SCVL</strong> +0.8%, <strong>REX</strong> +0.7%</li></ul><p><strong>Select MU peers/related names showing strength</strong>:</p><ul><li><strong>WDC</strong> +3.8%, <strong>AMD</strong> +1.4%, <strong>STX</strong> +1.2%, <strong>INTC</strong> +0.7%, . </li></ul><p><strong>Other news</strong>:</p><ul><li><strong>RGLS</strong> +23.6% ( Chairman disclosed purchase of 500K shares, worth more than $600K)</li><li><strong>SNAK</strong> +10.4% (light volume; sells Fresh Frozen Foods to The Pictsweet in a cash transaction for approximately $23.7 mln; previously-announced strategic review remains ongoing)</li><li><strong>SPHS</strong> +8.5% (announces that data from its successful Phase 2a study of topsalysin will be presented as a poster on March 26 at the 32nd Annual European Association of Urology in London, UK)</li><li><strong>QTNT</strong> +3.8% (announces that eight new rare antisera blood typing reagent products have been licensed for commercialization in the U.S. by the FDA)</li><li><strong>RXDX</strong> +3.4% (is exploring strategic options for taladegib and has entered into an amended and restated license, development and commercialization agreement with Eli Lilly (LLY) for the taladegib oncology program)</li><li><strong>GLOG</strong> +3.1% (GasLog Partners to purchase from GasLog (GLOG) 100% of the shares in the entity that owns and charters GasLog Greece)</li><li><strong>GLOP</strong> +1.9% (GasLog Partners to purchase from GasLog (GLOG) 100% of the shares in the entity that owns and charters GasLog Greece)</li><li><strong>NVO</strong> +1.8% (announces the CHMP provided a positive opinion for an EU label update for Tresiba)</li><li><strong>A</strong> +1.7% (favorable commentary on Thursday's Mad Money)</li><li><strong>NVDA</strong> +1.3% (announces that Tencent (TCEHY) Cloud will adopt NVIDIA Tesla GPU)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>ZSAN</strong> +5.6% (initiated with a Overweight at Piper Jaffray)</li><li><strong>UAA</strong> +4.1% (upgraded to Buy from Hold at Jefferies)</li><li><strong>PVH</strong> +1.4% (upgraded to Buy from Neutral at Citigroup)</li><li><strong>UN</strong> +0.7% (upgraded to Overweight from Equal Weight at Barclays)</li><li><strong>ADBE</strong> +0.5% (upgraded to Outperform from Neutral at Credit Suisse)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>FINL</strong> -15%, <strong>GME</strong> -10.8%, <strong>SPWH</strong> -10.5%, <strong>OXM</strong> -8.7%, <strong>CBAY</strong> -8.7%, <strong>OPGN</strong> -6.3%, <strong>ENV</strong> -1.4%, <strong>KLDX</strong> -1.1%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>XENE</strong> -44.2% (announces XEN801 did not meet efficacy endpoints in phase 2 clinical trial in patients with moderate to severe acne)</li><li><strong>MDGS</strong> -22.9% (pricing of a best efforts public offering of 979,714 Class A Units at a purchase price per unit of $3.50 and of 1,163,144 Class B Units at an effective purchase price per unit of $3.50)</li><li><strong>ADPT</strong> -8.8% (receives NYSE notice of non-compliance regarding late form 10-K filing; will have six months from March 16, 2017 to file)</li><li><strong>CDOR</strong> -6.7% (prices offering of 4.15 mln shares of common stock at $10.50 per share)</li><li><strong>MYL</strong> -3.9% (Abbott Laboratories (ABT) lowers active stake to 4.81% after selling a total of 44 mln Ordinary Shares through a privately-negotiated block trade at a price of $41.60 per Ordinary Share, not including discounts and commission)</li><li><strong>CHMI</strong> -1.8% (prices public offering of 4.5 mln shares of common stock at $16.50 per share)</li><li><strong>M</strong> -1.1% (elected Jeff Gennette CEO, effective today)</li><li><strong>FL</strong> -1.1% (in sympathy with FINL)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>TNDM</strong> -4% (downgraded to Neutral from Buy at B. Riley)</li><li><strong>M</strong> -1.1% (downgraded to Neutral from Buy at Citigroup)</li></ul>"